Background: Cisplatin-based regimens represent the standard chemotherapy in locally advanced/metastatic NSCLC. The presence of various comorbidities and/or renal impairment makes elderly patients poor candidates for such therapies. Several studies reported a better profile of tolerability for weekly infusion of paclitaxel (P) and/or carboplatin (Cb). The aim of this phase II study was to confirm the activity and feasibility of weekly P–Cb in elderly patients with locally advanced/metastatic NSCLC. Patients and methods: From May 2002 to December 2003 we consecutively recruited 18 ‘chemo-naive’ elderly pts with advanced NSCLC. The main characteristics of pts were: M12:F6, adenocarcinoma 8/18, epidermoidal 10/18, stage IIIB 6/18, stage ...
BACKGROUND: Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung...
The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably ...
The optimal management of unresectable locally advanced non-small-cell lung cancer in older patients...
Background: Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for l...
AbstractBackgroundPaclitaxel and platinum-based chemotherapy is considered to be a standard approach...
BackgroundAdministration of paclitaxel on a weekly schedule in combination with carboplatin is assoc...
IntroductionWe designed this phase II trial to evaluate the efficacy and safety of weekly paclitaxel...
AbstractBackgroundPaclitaxel and platinum-based chemotherapy is considered to be a standard approach...
Introduction: Lung cancer is the leading cause of tumour-related deaths in the elderly population bu...
[[abstract]]Paclitaxel plus carboplatin (CAR) or cisplatin (CIS) has shown activity in the treatment...
[[abstract]]Paclitaxel plus carboplatin (CAR) or cisplatin (CIS) has shown activity in the treatment...
[[abstract]]Paclitaxel plus carboplatin (CAR) or cisplatin (CIS) has shown activity in the treatment...
BackgroundAdministration of paclitaxel on a weekly schedule in combination with carboplatin is assoc...
PurposeIn this study our aim was to compare efficacy and toxicity profiles of two different schedule...
Abstract:Paclitaxel plus carboplatin (CAR) or cisplatin (CIS) has shown activity in the treatment of...
BACKGROUND: Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung...
The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably ...
The optimal management of unresectable locally advanced non-small-cell lung cancer in older patients...
Background: Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for l...
AbstractBackgroundPaclitaxel and platinum-based chemotherapy is considered to be a standard approach...
BackgroundAdministration of paclitaxel on a weekly schedule in combination with carboplatin is assoc...
IntroductionWe designed this phase II trial to evaluate the efficacy and safety of weekly paclitaxel...
AbstractBackgroundPaclitaxel and platinum-based chemotherapy is considered to be a standard approach...
Introduction: Lung cancer is the leading cause of tumour-related deaths in the elderly population bu...
[[abstract]]Paclitaxel plus carboplatin (CAR) or cisplatin (CIS) has shown activity in the treatment...
[[abstract]]Paclitaxel plus carboplatin (CAR) or cisplatin (CIS) has shown activity in the treatment...
[[abstract]]Paclitaxel plus carboplatin (CAR) or cisplatin (CIS) has shown activity in the treatment...
BackgroundAdministration of paclitaxel on a weekly schedule in combination with carboplatin is assoc...
PurposeIn this study our aim was to compare efficacy and toxicity profiles of two different schedule...
Abstract:Paclitaxel plus carboplatin (CAR) or cisplatin (CIS) has shown activity in the treatment of...
BACKGROUND: Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung...
The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably ...
The optimal management of unresectable locally advanced non-small-cell lung cancer in older patients...